Rubix LS | Top eClinical Trial Management Consulting/Service Company
Pharma Tech Outlook

Pharma Tech Outlook

Rubix LS
Bridging the Gap between Product Innovation and Patient Outcomes

Rubix LS: Bridging the Gap between Product Innovation and Patient Outcomes

Reginald Swift, Founder & CEO, Rubix LS Reginald Swift, Founder & CEO
At a time when demand for quality medication and efficient drug discovery for the evolving infections and diseases is higher than ever, healthcare and pharma communities are facing daunting challenges. The traditional ways of gathering huge volumes of data sets provide little visibility and insights into the genesis of a disease or the individuality of the person afflicted with the disease. In spite of having massive data sets, institutions such as the World Health Organization (WHO), the National Institute of Health (NIH), CROs, non-profits, and pharma companies struggle to dive deeper into the theoretical, physical, and genealogical information. Thus, legacy data delivery approaches hamper overall productivity and efficiency of drug discovery.

Lawrence, Massachusetts based R&D company, Rubix LS, is redefining data delivery in drug innovation. The company assists CROs as well as clinical and pharma sponsors in successfully completing the drug research, in time and in the budget. A customer-centric company, Rubix, designs a unique system based on the client’s needs. The system allows clients to aggregate data in such a way that they can not only harness data sets, including biomarkers and digital endpoints but also create a digital library that can be downloaded in real-time. “By understanding the precursor of a disease, we can actively predict how the disease can affect people in real-time,” says Reginald Swift, Founder and CEO of Rubix. “Using these insights, clients can model effective therapies, vaccines, and other innovative solutions that are a sure-fire way to fight specific diseases.”

Rubix designs systems from a real-world evidence perspective. To elaborate, the company engages the right patients to participate in the clinical trials and become part of the research, regardless of the process being virtual, digital, or onsite. “We understand what types of biological targets are already present with the client and what each client is trying to represent,” says Swift.

Subsequently, Rubix sets up the system along with the sensors, hardware, and software used for data analysis. The insights generated are channeled to the CROs or sponsor sites for effective and informed decision making.

By understanding the precursor of a disease, we can actively predict how the disease can affect people in real-time


Playing an active role in every stage of the drug development lifecycle, Rubix digitally transforms the R&D process. As Rubix’s system guarantees seamless data flow throughout the innovation cycle, clients can conduct virtual clinical trials easily. They can deliver information digitally across various stages and departments, including clinical trials, regulatory checks, manufacturing, and supply chain. With such capabilities, organizations become more nimble and cost-efficient in product development. For instance, if there are many complaints about a newly release drug, Rubix records that information through its post-market surveillance mechanism and turns that data into real-world evidence format. This data is channeled back into the product development to target specific areas such as gene development and gene editing for better drug effectiveness.

As a case study, a clinical sponsor from a remote location lacked valuable data related to certain diseases. Rubix entered the scene and created an infrastructure for remote patient engagement and monitoring for the clinical study. The company recruited 316 patients in six weeks with a 94 percent retention rate. It also helped the client design a customized system to recruit the villagers and the individuals in the community for trials. In addition, Rubix engaged the health agencies to undertake Phase I and II safety trial and develop a new vaccine for treating the specific infectious or deadly disease.

Moving forward, Rubix plans to partner with international organizations and enhance its clinical trial data delivery for greater research outcomes. The company also aims to make an impact on the communities in Brazil, South Asia, and Africa.

Rubix LS News

Rubix LS Reveals Groundbreaking Access to Over 12 Million Diverse Patient Data Sets

Paving the Way for Revolutionary Healthcare Research

LAWRENCE - Rubix LS, announce a significant milestone in its mission to transform patient care: the acquisition and utilization of an extensive data repository featuring over 12 million (13,981,289) diverse patient records. This development represents a significant leap forward in the company's ability to drive research and develop targeted therapies for special populations.

"Our access to over 12 million diverse patient data sets is a testament to our commitment to understanding and addressing the unique healthcare needs of diverse communities," said Dr. Reginald Swift, CEO of Rubix LS. "This vast and rich data pool is more than just numbers – it's a window into the varied health experiences and needs of people from all walks of life."

The comprehensive patient data sets are expected to transform how Rubix LS approaches healthcare research, offering unprecedented insights into patient demographics, disease patterns, treatment outcomes, and more.

This level of data granularity allows for more precise and culturally sensitive research. Leading to the development of more effective and personalized healthcare solutions.

"The depth and diversity of our patient data are key in driving innovation in healthcare," added Tara Mitchell, Rubix LS's chief biomedical scientist. "This information enables us to tailor our research and development efforts, ensuring that the therapies and solutions we work on are genuinely suited to the needs of those we aim to serve, particularly in underserved communities."

Rubix LS's expansive patient data repository is a resource for developing new therapies and a tool for understanding the broader implications of health trends and disparities. The company is positioned to make significant contributions to the fields of medical research and public health, especially in addressing conditions that disproportionately affect special populations.

This milestone underscores Rubix LS’s role as a pioneer in leveraging big data for healthcare advancement. With this extensive database at its disposal, Rubix LS is committed to leading the way in creating a more inclusive and effective healthcare landscape.

For further information and insights into how Rubix LS is utilizing these patient data sets to revolutionize healthcare research, please visit rubixls.com

BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

Vancouver, British Columbia - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening program, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), by focusing on reaching underserved communities. This collaboration combines the innovative strengths of both organizations to develop accessible, non-invasive, and accurate diagnostic solutions that promise to set new standards in early detection and personalized cancer treatment.

Breast and lung cancers are among the leading health challenges for women worldwide, with early detection being crucial for successful treatment outcomes. However, access to early screening and diagnostics remains a significant barrier, particularly in underserved communities. Recognizing this, Rubix LS and BioMark are dedicating their partnership to advancing cancer detection technologies and ensuring these innovations reach those most in need.

Rashid Bux, CEO of BioMark, emphasized the importance of inclusivity in healthcare innovation, stating, "Over the past year, we have laid the groundwork for today's partnership through extensive interactions with members of underserved communities at major society meetings and individually. Our collaboration with Rubix LS is a step towards democratizing access to advanced healthcare solutions, bridging the healthcare equity gap, and making early cancer detection a reality for everyone, regardless of their geographic or socio-economic status."

The initiative will harness Rubix LS's strength as a culturally competent research catalyst, with CLIA/CAP clinical laboratory capacity to perform screening and conducting necessary clinical studies working in harmony with BioMark's expertise in translating blood-based biomarker research into laboratory-developed diagnostic tests (LDT) that are not only effective but also widely accessible. Central to this effort is the deployment of mobile diagnostics and telehealth services, meticulously designed to bridge the gap in healthcare access and extend advanced cancer screening technologies to remote and underserved communities. This approach underscores a commitment to equity, ensuring that state-of-the-art healthcare solutions reach all segments of the population, particularly those in areas traditionally neglected by advancements in medical technology.

Top 10 eClinical Trial Management Consulting/Service Companies - 2020

Company
Rubix LS

Management
Reginald Swift, Founder & CEO

Description
Offers innovative ways to data delivery that assist CROs as well as clinical and pharma sponsors in successfully completing the drug research, in time and in the budget